<?xml version="1.0" encoding="UTF-8"?>
<p id="p0140">Oseltamivir is recommended to treat and prevention of Influenza A and Influenza B viruses. It belongs to the class of neuraminidase inhibitors and acts as a competitive inhibitor of neuraminidase enzyme present in influenza virus and prevents the respiratory tract infections. This enzyme involved in the cleavage of the sialic acid which is an important component of glycoproteins present on the surface of human cells and helps new virions to exit the cells [
 <xref rid="bb0555" ref-type="bibr">111</xref>]. The therapeutic potential of Oseltamavir on SARS-CoV-2 infections need to be evaluated. Few of the combinational drugs such as ASC09F and Ritonavir are being evaluated together with Oseltamivir, these are under the clinical trials now.
</p>
